Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
04 2020
Historique:
received: 05 09 2019
revised: 13 12 2019
accepted: 19 12 2019
pubmed: 31 12 2019
medline: 11 7 2020
entrez: 30 12 2019
Statut: ppublish

Résumé

Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development. Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) RESULTS: After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05-1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03-1.12; P = 3.3 × 10 In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.

Sections du résumé

BACKGROUND & AIMS
Human studies examining associations between circulating levels of insulin-like growth factor 1 (IGF1) and insulin-like growth factor binding protein 3 (IGFBP3) and colorectal cancer risk have reported inconsistent results. We conducted complementary serologic and Mendelian randomization (MR) analyses to determine whether alterations in circulating levels of IGF1 or IGFBP3 are associated with colorectal cancer development.
METHODS
Serum levels of IGF1 were measured in blood samples collected from 397,380 participants from the UK Biobank, from 2006 through 2010. Incident cancer cases and cancer cases recorded first in death certificates were identified through linkage to national cancer and death registries. Complete follow-up was available through March 31, 2016. For the MR analyses, we identified genetic variants associated with circulating levels of IGF1 and IGFBP3. The association of these genetic variants with colorectal cancer was examined with 2-sample MR methods using genome-wide association study consortia data (52,865 cases with colorectal cancer and 46,287 individuals without [controls]) RESULTS: After a median follow-up period of 7.1 years, 2665 cases of colorectal cancer were recorded. In a multivariable-adjusted model, circulating level of IGF1 associated with colorectal cancer risk (hazard ratio per 1 standard deviation increment of IGF1, 1.11; 95% confidence interval [CI] 1.05-1.17). Similar associations were found by sex, follow-up time, and tumor subsite. In the MR analyses, a 1 standard deviation increment in IGF1 level, predicted based on genetic factors, was associated with a higher risk of colorectal cancer risk (odds ratio 1.08; 95% CI 1.03-1.12; P = 3.3 × 10
CONCLUSIONS
In an analysis of blood samples from almost 400,000 participants in the UK Biobank, we found an association between circulating level of IGF1 and colorectal cancer. Using genetic data from 52,865 cases with colorectal cancer and 46,287 controls, a higher level of IGF1, determined by genetic factors, was associated with colorectal cancer. Further studies are needed to determine how this signaling pathway might contribute to colorectal carcinogenesis.

Identifiants

pubmed: 31884074
pii: S0016-5085(19)41951-3
doi: 10.1053/j.gastro.2019.12.020
pmc: PMC7152801
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
IGF1 protein, human 0
IGF2 protein, human 0
IGFBP3 protein, human 0
Insulin-Like Growth Factor Binding Protein 3 0
Insulin-Like Growth Factor I 67763-96-6
Insulin-Like Growth Factor II 67763-97-7

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1300-1312.e20

Subventions

Organisme : NCI NIH HHS
ID : R01 CA059045
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074799
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : K05 CA154337
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA201407
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA196569
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000421
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100001C
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_12028
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U24 CA074800
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 10589
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074806
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA037429
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074794
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034987
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA137088
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA076366
Pays : United States
Organisme : Cancer Research UK
ID : 19167
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U19 CA148107
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES013678
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189974
Pays : United States
Organisme : NIA NIH HHS
ID : HHSN271201100004C
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA207371
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA189184
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : Cancer Research UK
ID : C490/A16561
Pays : United Kingdom
Organisme : Medical Research Council
ID : 1000143
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA167551
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201500005C
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100004C
Pays : United States
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C570/A16491
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA182883
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA122839
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C588/A19167
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA074800
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100046C
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100003C
Pays : United States
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : KL2 TR002317
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA042182
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074794
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074806
Pays : United States
Organisme : Medical Research Council
ID : MR/L01629X/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA136726
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206110
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100002C
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA097735
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA074799
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA153323
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA097325
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200008I
Pays : United States
Organisme : NCI NIH HHS
ID : K05 CA152715
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197350
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063464
Pays : United States
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P01 CA033619
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA074783
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States

Informations de copyright

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Références

Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
Int J Endocrinol. 2010;2010:
pubmed: 20885914
J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600
pubmed: 11018095
J Biol Chem. 1995 Jun 9;270(23):13589-92
pubmed: 7539790
Int J Cancer. 2019 Sep 1;145(5):1238-1244
pubmed: 31131883
Lancet. 1990 Mar 31;335(8692):765-74
pubmed: 1969518
Br J Cancer. 2006 Jul 3;95(1):112-7
pubmed: 16804529
J Bone Miner Res. 2011 Sep;26(9):2298-306
pubmed: 21590739
Front Oncol. 2018 Apr 16;8:103
pubmed: 29713614
Oncogene. 2017 Sep 21;36(38):5341-5355
pubmed: 28534511
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Cancer Res. 2008 Jan 1;68(1):329-37
pubmed: 18172327
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5
pubmed: 15824155
Nat Genet. 2021 Feb;53(2):185-194
pubmed: 33462484
J Natl Cancer Inst. 1999 Apr 7;91(7):620-5
pubmed: 10203281
Endocr Rev. 2007 Feb;28(1):20-47
pubmed: 16931767
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Eur J Epidemiol. 2015 Jul;30(7):543-52
pubmed: 25773750
Gastroenterology. 2004 Apr;126(4):964-70
pubmed: 15057734
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3108-15
pubmed: 18990751
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
Mol Pathol. 2001 Jun;54(3):145-8
pubmed: 11376125
Bioinformatics. 2019 Nov 1;35(22):4851-4853
pubmed: 31233103
Int J Cancer. 2003 Oct 20;107(1):89-93
pubmed: 12925961
Eur Heart J. 2008 Mar;29(6):800-9
pubmed: 18303034
Science. 2003 Mar 14;299(5613):1753-5
pubmed: 12637750
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
J Natl Cancer Inst. 2015 Aug 01;107(10):
pubmed: 26232761
Int J Cancer. 1994 Aug 1;58(3):452-9
pubmed: 8050827
Cancer Res. 2003 Nov 15;63(22):7708-16
pubmed: 14633695
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
Mol Pathol. 2001 Jun;54(3):133-7
pubmed: 11376123
Br J Cancer. 2001 Nov 30;85(11):1695-9
pubmed: 11742490
J Clin Endocrinol Metab. 2001 Mar;86(3):1274-80
pubmed: 11238520
Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):345-9
pubmed: 10794477
Front Oncol. 2015 Oct 15;5:230
pubmed: 26528439
Aging Cell. 2016 Oct;15(5):811-24
pubmed: 27329260
Am J Epidemiol. 2010 Aug 15;172(4):407-18
pubmed: 20634278
Growth Horm IGF Res. 2015 Apr;25(2):90-5
pubmed: 25641638
Nat Genet. 2019 Jan;51(1):76-87
pubmed: 30510241
Int J Cancer. 2007 May 1;120(9):2007-12
pubmed: 17266031
Cell Metab. 2014 Mar 4;19(3):407-17
pubmed: 24606898
Am J Epidemiol. 1999 Aug 15;150(4):341-53
pubmed: 10453810
Cancer Causes Control. 2012 Jun;23(6):907-17
pubmed: 22527168
Int J Cancer. 2010 Apr 1;126(7):1702-15
pubmed: 19810099
Int J Biochem Cell Biol. 1996 Jun;28(6):619-37
pubmed: 8673727

Auteurs

Neil Murphy (N)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France. Electronic address: murphyn@iarc.fr.

Robert Carreras-Torres (R)

Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Mingyang Song (M)

Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Andrew T Chan (AT)

Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Richard M Martin (RM)

MRC Integrative Epidemiology Unit (IEU), Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Bristol Medical School, Department of Population Health Sciences, University of Bristol, Bristol, UK; National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, University Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK.

Nikos Papadimitriou (N)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

Niki Dimou (N)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

Konstantinos K Tsilidis (KK)

Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Barbara Banbury (B)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Kathryn E Bradbury (KE)

National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand.

Jelena Besevic (J)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Sabina Rinaldi (S)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

Elio Riboli (E)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Amanda J Cross (AJ)

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

Ruth C Travis (RC)

Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Claudia Agnoli (C)

Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Demetrius Albanes (D)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Sonja I Berndt (SI)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Stéphane Bézieau (S)

Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France.

D Timothy Bishop (DT)

Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Daniel D Buchanan (DD)

Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria 3010, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria 3010, Australia; Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

N Charlotte Onland-Moret (NC)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Andrea Burnett-Hartman (A)

Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.

Peter T Campbell (PT)

Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.

Graham Casey (G)

Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia.

Sergi Castellví-Bel (S)

Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

María-Dolores Chirlaque (MD)

Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, Murcia, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain.

Albert de la Chapelle (A)

Department of Cancer Biology and Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Dallas English (D)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.

Jane C Figueiredo (JC)

Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles California.

Steven J Gallinger (SJ)

Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Graham G Giles (GG)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

Stephen B Gruber (SB)

Department of Preventive Medicine & USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.

Andrea Gsur (A)

Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria.

Jochen Hampe (J)

Department of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany.

Heather Hampel (H)

Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Tabitha A Harrison (TA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Michael Hoffmeister (M)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Li Hsu (L)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Biostatistics, University of Washington, Seattle, Washington.

Wen-Yi Huang (WY)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Jeroen R Huyghe (JR)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Mark A Jenkins (MA)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.

Temitope O Keku (TO)

Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina.

Tilman Kühn (T)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sun-Seog Kweon (SS)

Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea; Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun, Korea.

Loic Le Marchand (L)

University of Hawaii Cancer Center, Honolulu, Hawaii.

Christopher I Li (CI)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Li Li (L)

Department of Family Medicine, University of Virginia, Charlottesville, Virginia.

Annika Lindblom (A)

Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.

Vicente Martín (V)

CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Biomedicine Institute (IBIOMED), University of León, León, Spain.

Roger L Milne (RL)

Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.

Victor Moreno (V)

Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain; CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain.

Polly A Newcomb (PA)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; School of Public Health, University of Washington, Seattle, Washington.

Kenneth Offit (K)

Clinical Genetics Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.

Shuji Ogino (S)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Jennifer Ose (J)

Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.

Vittorio Perduca (V)

CESP (Inserm U1018), Fac. de médecine - Université Paris-Saclay, Fac. de médecine - UVSQ, 94805, Villejuif, France; Gustave Roussy, F-94805, Villejuif, France; Laboratoire de Mathématiques Appliquées MAP5 (UMR CNRS 8145), Université Paris Descartes, France.

Amanda I Phipps (AI)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology, University of Washington, Seattle, Washington.

Elizabeth A Platz (EA)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

John D Potter (JD)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Centre for Public Health Research, Massey University, Wellington, New Zealand.

Conghui Qu (C)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Gad Rennert (G)

Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Lori C Sakoda (LC)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Research, Kaiser Permanente Northern California, Oakland, California.

Clemens Schafmayer (C)

Department of General and Thoracic Surgery, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Robert E Schoen (RE)

Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Martha L Slattery (ML)

Department of Internal Medicine, University of Utah, Salt Lake City, Utah.

Catherine M Tangen (CM)

SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Cornelia M Ulrich (CM)

Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.

Franzel J B van Duijnhoven (FJB)

Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, the Netherlands.

Bethany Van Guelpen (B)

Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden; Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.

Kala Visvanathan (K)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Pavel Vodicka (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic; Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.

Ludmila Vodickova (L)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic; Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.

Veronika Vymetalkova (V)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czech Republic; Faculty of Medicine and Biomedical Center in Pilsen, Charles University, Pilsen, Czech Republic.

Hansong Wang (H)

University of Hawaii Cancer Center, Honolulu, Hawaii.

Emily White (E)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology, University of Washington, Seattle, Washington.

Alicja Wolk (A)

Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.

Michael O Woods (MO)

Memorial University of Newfoundland, Discipline of Genetics, St. John's, Canada.

Anna H Wu (AH)

University of Southern California, Preventive Medicine, Los Angeles, California.

Wei Zheng (W)

Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.

Ulrike Peters (U)

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Epidemiology, University of Washington, Seattle, Washington.

Marc J Gunter (MJ)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH